Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08

  • Patrick Y. Wen
  • , W. K.Alfred Yung
  • , Kathleen R. Lamborn
  • , Patricia L. Dahia
  • , Yanfeng Wang
  • , Bin Peng
  • , Lauren E. Abrey
  • , Jeffrey Raizer
  • , Timothy F. Cloughesy
  • , Karen Fink
  • , Mark Gilbert
  • , Susan Chang
  • , Larry Junck
  • , David Schiff
  • , Frank Lieberman
  • , Howard A. Fine
  • , Minesh Mehta
  • , H. Ian Robins
  • , Lisa M. DeAngelis
  • , Morris D. Groves
    • Vinay K. Puduvalli, Victor Levin, Charles Conrad, Elizabeth A. Maher, Kenneth Aldape, Michael Hayes, Laurie Letvak, Merrill J. Egorin, Renaud Capdeville, Richard Kaplan, Anthony J. Murgo, Charles Stiles, Michael D. Prados

Research output: Contribution to journal › Article › peer-review

364 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science